Rabbit Recombinant Monoclonal TDO2/TDO antibody. Suitable for ICC/IF, IP, WB and reacts with Human, Mouse, Rat samples.
IgG
Rabbit
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
ICC/IF | IP | WB | IHC-P | IHC-Fr | Flow Cyt (Intra) | |
---|---|---|---|---|---|---|
Human | Tested | Tested | Tested | Not recommended | Not recommended | Not recommended |
Mouse | Expected | Tested | Tested | Not recommended | Not recommended | Not recommended |
Rat | Expected | Expected | Tested | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/30 | Notes - |
Species Human | Dilution info 1/30 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 | Notes - |
Species Rat | Dilution info 1/1000 | Notes - |
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat, Human | Dilution info - | Notes - |
Heme-dependent dioxygenase that catalyzes the oxidative cleavage of the L-tryptophan (L-Trp) pyrrole ring and converts L-tryptophan to N-formyl-L-kynurenine. Catalyzes the oxidative cleavage of the indole moiety.
TDO, Tryptophan oxygenase, Tryptophan pyrrolase, Tryptophanase, TO, TRPO, TDO2, TDO
Rabbit Recombinant Monoclonal TDO2/TDO antibody. Suitable for ICC/IF, IP, WB and reacts with Human, Mouse, Rat samples.
IgG
Rabbit
Preservative: 0.01% Sodium azide
Constituents: 59.94% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Liquid
Monoclonal
EPR23745-311
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
-20°C
Upon delivery aliquot
Avoid freeze / thaw cycle
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This supplementary information is collated from multiple sources and compiled automatically.
TDO2 also known as tryptophan 23-dioxygenase is an enzyme that catalyzes the initial and rate-limiting step in the kynurenine pathway degrading tryptophan to N-formylkynurenine. This reaction is important for regulating systemic tryptophan levels. TDO2 is a heme-containing enzyme with a molecular mass of approximately 53 kDa. It is highly expressed in the liver unlike its counterpart indoleamine 23-dioxygenase (IDO) which has wider tissue distribution. Liver-specific expression suggests its role in orchestrating whole-body tryptophan metabolism.
TDO2 plays a significant role in maintaining immune tolerance and modulating neurotransmitter levels. While not part of a larger complex it interacts with several other proteins to mediate its effects. By controlling tryptophan availability TDO2 impacts the production of serotonin and downstream kynurenine metabolites affecting neural and immune functions. Its activity influences both central nervous system processes and peripheral immune responses implying a broad impact on various physiological systems.
TDO2's function integrates into the kynurenine and serotonin pathways. In the kynurenine pathway TDO2's enzymatic activity leads to the generation of metabolites such as kynurenine and quinolinic acid which have immunoregulatory and excitotoxic properties. The serotonin pathway also indirectly involves TDO2 as it limits tryptophan's availability for serotonin synthesis. TDO2 interacts with IDO in controlling the balance of tryptophan metabolites providing a link between immune signaling and central nervous system regulation.
TDO2 has been implicated in cancer and neurodegenerative diseases. Overexpression of TDO2 is observed in various cancers where it helps create an immune-suppressive environment that aids tumor survival. The enzyme’s upregulation affects tumor microenvironment dynamics often acting in concert with IDO which further mediates immune escape. TDO2's activity may also contribute to neurodegenerative disorders through its impact on kynurenine pathway metabolites which can be neurotoxic. The interplay between TDO2 and IDO suggests that targeting this enzymatic pathway could offer therapeutic avenues in both oncological and neuropsychiatric conditions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
The the expression pattern and observed MW is consistent with what has been described in the literature (PMID: 27573671, PMID: 25691885)
Negative control: pancreas (PMID:25691885).
Exposure time: 26 seconds
All lanes: Western blot - Anti-TDO2/TDO antibody [EPR23745-311] (ab259359) at 1/1000 dilution
Lane 1: Human liver tissue lysate at 40 µg
Lane 2: Human pancreas tissue lysate at 40 µg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 48 kDa
Blocking and diluting buffer and concentration: 5% NFDM/TBST
The expression pattern and observed MW is consistent with what has been described in the literature (PMID:25691885, PMID: 10775460).
Negative control: pancreas (PMID:25691885).
Exposure time: 26 seconds.
All lanes: Western blot - Anti-TDO2/TDO antibody [EPR23745-311] (ab259359) at 1/1000 dilution
Lane 1: Mouse liver tissue lysate at 40 µg
Lane 2: Mouse pancreas tissue lysate at 40 µg
Lane 3: Rat liver tissue lysate at 40 µg
Lane 4: Rat pancreas tissue lysate at 40 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution
Predicted band size: 48 kDa
Observed band size: 43 kDa
This data was developed using 259359, the same antibody clone in a different buffer formulation.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
The expression pattern and observed MW is consistent with what has been described in the literature (PMID:25691885, PMID: 10775460).
Negative control: pancreas (PMID:25691885).
Exposure time: 26 seconds.
TDO2/TDO was immunoprecipitated from 0.35 mg Human liver tissue lysate 10 ug with ab259359 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab259359 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: Human liver tissue lysate 10 ug
Lane 2: ab259359 IP in Human liver tissue lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab259359 in human liver tissue lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
All lanes: Immunoprecipitation - Anti-TDO2/TDO antibody [EPR23745-311] (ab259359)
Predicted band size: 48 kDa
Immunofluorescent analysis of 4% Paraformaldehyde-fixed, 0.1% TritonX-100 permeabilized 293T cells labelling TDO2/TDO with ab259359 at 1/500 (1.072 ug/ml) dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) ab150080 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) antibody at 1/500 dilution (Green) Confocal image showing cytoplasmic staining in 293T cells transfected with myc-tagged TDO2 expression vector. is observed. Myc-Tag Mouse mAb (Alexa Fluor® 488) was used to counterstain tubulin at 1/100 dilution (Red). The Nuclear counterstain was DAPI (Blue). Secondary antibody only control: Secondary antibody is Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) ab150080 Goat Anti-Rabbit IgG H&L (Alexa Fluor® 594) at 1/500 dilution.
TDO2/TDO was immunoprecipitated from 0.35 mg Mouse liver tissue lysate 10 ug with ab259359 at 1/30 dilution (2ug in 0.35mg lysates). Western blot was performed on the immunoprecipitate using ab259359 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(VeriBlot for IP Detection Reagent (HRP) ab131366) was used at 1/5000 dilution.
Lane 1: Mouse liver tissue lysate 10 ug
Lane 2: ab259359 IP in Mouse liver tissue lysate
Lane 3: Rabbit monoclonal IgG (Rabbit IgG, monoclonal [EPR25A] - Isotype Control ab172730) instead of ab259359 in mouse liver tissue lysate
Blocking and dilution buffer and concentration: 5% NFDM/TBST.
Exposure time: 3 minutes.
All lanes: Immunoprecipitation - Anti-TDO2/TDO antibody [EPR23745-311] (ab259359)
Predicted band size: 48 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com